ArticleNeurosurgical review2025
Surgical outcomes of Spetzler-Martin grade III arteriovenous malformations in the multimodality era: a single centre retrospective cohort study.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spetzler-Martin (SM) grade III arteriovenous malformations lie at the borderline between low- and high-risk lesions, so their ideal management strategy is still debated. We aim to examine functional, angiographic and seizure outcomes after modern microsurgical treatment of SM grade III arteriovenous malformations (AVMs) and to assess prognostic factors within Lawton sub-groups. We retrospectively reviewed 45 consecutive SM grade III AVMs resected between January 2014 and December 2023. Demographics, nidus morphology, use of pre-operative embolization, surgical obliteration, complications, modified Rankin Scale (mRS) and modified Engel seizure class were recorded at discharge, 6 months and 1 year. Multivariate logistic regression identified predictors of unfavourable outcome (mRS > 2). Mean age was 26 years. 64% were male. Pre operative embolization was employed in 44%, predominantly S2E0V1 lesions which correlated with eloquence (p = 0.005) and nidus size > 3 cm (p = 0.04). Gross-total resection was achieved in 9% (41/45). New neurological deficits occurred in 1% overall but were permanent in 7%. Favourable mRS (≤ 2) improved from 7% pre-operatively to 4% at one year. Engel I seizure freedom reached 3%. Only baseline mRS > 2 independently predicted unfavourable outcome (adjusted OR 20.0, 5% CI 3.7-108.2; p = 0.001). Modern microsurgery supported by selective embolization, neuro-monitoring and indocyanine-green video-angiography delivers high cure and low permanent morbidity for most SM-III AVMs. Functional prognosis depends chiefly on baseline status, underscoring the value of early referral.
Indexed as
Identifiers
41291088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.